All terms
Investment & FinanceStartup Lifecycle
Post-Money Valuation
Company valuation immediately after a financing closes.
Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 5, 2026
Definition
Post-money valuation equals pre-money valuation plus the amount of new capital raised. Investor ownership equals investment ÷ post-money. For example, a 5 million dollar investment at a 20 million dollar post-money gives the investor 25 percent. Post-money is also used to define ownership in post-money SAFEs. Because it includes new cash, post-money is not the same as the value of the business before the deal. What the regulation says
While 'post-money valuation' is an investment and finance term, its direct impact on regulatory and quality aspects of MedTech is indirect. Regulatory bodies like the FDA or those overseeing EU MDR do not directly regulate company valuations. However, a company's valuation can influence its ability to fund significant regulatory submissions, quality system improvements, or post-market surveillance activities, which are critical under regulations like 21 CFR 820 (Quality System Regulation) and EU MDR Annex III.What this means in practice
Post-money is the headline number in press releases. Founders should focus on the dilution math, not the headline.Examples
- A MedTech startup with a $100 million post-money valuation successfully secures funding to conduct a pivotal clinical trial required for FDA premarket approval (PMA).
- A company's $20 million post-money valuation, while substantial, is carefully managed to ensure adequate funds are reserved for ongoing post-market surveillance activities mandated by EU MDR Article 83.
- An investor evaluating a MedTech company with a high post-money valuation examines its cash burn rate to confirm sustained funding for achieving compliance with ISO 13485:2016 quality management system requirements.
Common pitfalls
- •A high post-money valuation does not guarantee regulatory approval or product market success.
- •Confusing a high valuation with adequate funding for long-term regulatory compliance can lead to underestimation of compliance costs.
- •Failing to allocate sufficient capital from funding rounds, regardless of valuation, for critical quality and regulatory personnel can hinder compliance.
- •Assuming investors fully understand the financial requirements for MedTech regulatory clearances and post-market obligations.
Frequently asked questions
Post-money valuation reflects the company's total estimated value after receiving new investment. While not a regulatory metric itself, a higher valuation can indicate greater financial resources, which are essential for funding the often-expensive regulatory processes, quality system implementation, and post-market activities required by authorities such as the FDA or under the EU MDR.
Related terms
Grouped by themeEditor's picks
· Hand-selected related conceptsMore in Investment & Finance
· Same categoryInvestment & Finance
409A Valuation
An independent fair-market-value appraisal of common stock used to set tax-compliant strike prices for employee stock options.
Investment & Finance
Anti-Dilution Protection
Adjustment that protects investors if the company raises a future round at a lower price.
Investment & Finance
Board of Directors
The governing body elected by stockholders that oversees management, approves major corporate actions, and typically includes investor-designated seats after venture financing.
Investment & Finance
Bridge Round
Interim financing between priced rounds, usually convertible.
Cited by
Where this term appears across MedTech Terms.
Ecosystems (1)
Latest in MedTech
Sources
4 sourcesSources support the definition or relevant regulatory context, not necessarily every claim on this page. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.
Tier 2Regulator guidance and consensus· 1Tier 4Trade press and expert commentary· 3
Link health: 4 verified· last checked 2026-06-20· added official documents checked 2026-11-01
PitchBook·1NVCA·1SVB·1U.S. Securities and Exchange Commission·1
- 1PitchBook - MedTech CoverageTier 4 VerifiedPitchBookpitchbook.com
- 2NVCA Model DocumentsTier 4 VerifiedNVCAnvca.org
- 3Silicon Valley Bank - Healthcare ReportsTier 4 VerifiedSVBsvb.com
- 4SEC capital-raising glossary: valuationTier 2 VerifiedU.S. Securities and Exchange Commissionsec.gov
Inline markers like [1] jump to the matching reference above.